Phase 1 Study of Sipuleucel-T and Ipilimumab in Combination for Advanced Prostate Cancer
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Antigen-specific memory T cell response
To quantify antigen-specific memory T cell response to sipuleucel-T and ipilimumab in combination.
After last sipuleucel-T and last ipilimumab, and follow-up period, an expected average of 15 months
Mark Scholz, MD
Prostate Oncology Specialists, Inc.
United States: Institutional Review Board
|Prostate Oncology Specialists, Inc.||Marina Del Rey, California 90292|